TD Cowen Lowers PT on MetLife (MET), Keeps a Buy

MetLife, Inc. (NYSE:MET) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 11, TD Cowen lowered the firm’s price target on MetLife, Inc. (NYSE:MET) from $91 to $88, while maintaining a Buy rating on the stock.

​The firm noted updating its financial model after the company’s Q4 2025 earnings were reported on February 4. During the quarter, the company grew its revenue by 22.56% year-over-year to $24.19 billion, but missed estimates by $7.44 billion. The EPS of $2.49 topped consensus by $0.15.

​Management noted that the quarterly performance was driven by a 12% year-over-year increase in Group Benefits adjusted earnings, which reached $465 million in Q4. Moreover, the Retirement and Income Solutions earnings also improved 18% year-over-year to $454 million.

​Notably, the MetLife Investment Management, which is the newly formed business segment, delivered $60 million in adjusted earnings for 2025. The segment’s assets under management reached $742 billion, up from about $600 billion a year earlier following the PineBridge acquisition.

​Looking ahead, the company expects fiscal 2026 to see double-digit adjusted EPS growth, along with adjusted ROE of 15% to 17%.

​MetLife, Inc. (NYSE:MET) provides insurance, annuities, employee benefits, and asset management services across the United States and international markets. Its operations include life, dental, disability, property, and casualty insurance, as well as retirement and savings products offered to individuals and institutions.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.